Phlda3 regulates beta cell survival during stress by Bensellam, Mohammed et al.
1Scientific RepoRtS |         (2019) 9:12827  | https://doi.org/10.1038/s41598-019-49289-5
www.nature.com/scientificreports
Phlda3 regulates beta cell survival 
during stress
Mohammed Bensellam1,2, Jeng Yie Chan1,3, Kailun Lee1, Mugdha V. Joglekar4, 
Anandwardhan A. Hardikar  4, Thomas Loudovaris5, Helen E. Thomas5,6,  
Jean-Christophe Jonas  2 & D. Ross Laybutt1,3
The loss of functional beta cell mass characterises all forms of diabetes. Beta cells are highly susceptible 
to stress, including cytokine, endoplasmic reticulum (ER) and oxidative stress. This study examined 
the role of pleckstrin homology-like, domain family A, member 3 (Phlda3) in beta cell survival under 
stress conditions and the regulatory basis. We found that the mRNA levels of Phlda3 were markedly 
upregulated in vivo in the islets of diabetic humans and mice. In vitro, exposure of MIN6 cells or islets to 
cytokines, palmitate, thapsigargin or ribose upregulated Phlda3 mRNA and protein levels, concurrent 
with the induction of ER stress (Ddit3 and Trb3) and antioxidant (Hmox1) genes. Furthermore, H2o2 
treatment markedly increased PHLDA3 immunostaining in human islets. Phlda3 expression was 
differentially regulated by adaptive (Xbp1) and apoptotic (Ddit3) unfolded protein response (UPR) 
mediators. siRNA-mediated knockdown of Xbp1 inhibited the induction of Phlda3 by cytokines 
and palmitate, whereas knockdown of Ddit3 upregulated Phlda3. Moreover, knockdown of Phlda3 
potentiated cytokine-induced apoptosis in association with upregulation of inflammatory genes (iNos, 
IL1β and IκBα) and NFκB phosphorylation and downregulation of antioxidant (Gpx1 and Srxn1) and 
adaptive UPR (Xbp1, Hspa5 and Fkbp11) genes. Knockdown of Phlda3 also potentiated apoptosis under 
oxidative stress conditions induced by ribose treatment. These findings suggest that Phlda3 is crucial 
for beta cell survival under stress conditions. Phlda3 regulates the cytokine, oxidative and ER stress 
responses in beta cells via the repression of inflammatory gene expression and the maintenance of 
antioxidant and adaptive UPR gene expression. Phlda3 may promote beta cell survival in diabetes.
The loss of functional beta cell mass plays a crucial role in the pathogenesis of both type 1 and type 2 diabe-
tes1. Compelling evidence has revealed that prolonged exposure to the (pre)diabetic milieu triggers beta cell 
stress and death. Indeed, inflammatory, endoplasmic reticulum (ER) and oxidative stress are potential mecha-
nisms through which cytokines and elevated levels of glucose and free fatty acids induce beta cell apoptosis2–6. 
This has been associated with the activation of numerous proapoptotic effectors such as Ddit3, Trb3, Txnip and 
c-Jun N-terminal kinase7–14. However, stress stimuli also activate defense and adaptive responses, including the 
unfolded protein response (UPR) and the antioxidant response, that maintain homeostasis and promote beta cell 
survival5,15,16. The balance between protective and deleterious responses to stress determines beta cell fate, but the 
pathways involved are not fully characterized5. A better understanding of the beta cell stress response signaling 
pathways is needed to identify novel targets to preserve the functional beta cell mass in (pre)diabetic individuals.
Phlda3 encodes for a member of the pleckstrin homology-like, domain family of proteins. The pleckstrin 
homology domain is an amino acid sequence of about 100 residues with a specific three-dimensional struc-
ture allowing binding to phosphoinositides and protein-protein interaction. It is present in a variety of proteins 
involved in signal transduction, phospholipid processing, membrane trafficking and organization of cytoskel-
eton17. The first member of this family, Phlda1, has previously been implicated in the modulation of energy 
metabolism and obesity18. On the other hand, Phlda3 has been identified as a tumor suppressor in pancreatic 
neuroendocrine tumors19, and its expression is induced by ER stress in hepatocytes20. However, whether Phlda3 
expression is altered in diabetes or plays a role in beta cell pathophysiology are unclear.
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In the present study, we report for the first time that Phlda3 expression is upregulated in the islets of dia-
betic rodents and humans. Our findings in isolated islets and MIN6 beta cells suggest that Phlda3 is induced 
in response to inflammatory, ER and oxidative stress and that it plays an important adaptive role during 
these stresses. Indeed, Phlda3 knockdown potentiates inflammatory- and oxidative stress-induced apoptosis. 
Mechanistically, we demonstrate that the adaptive UPR effector Xbp1 is required for Phlda3 induction, whereas 
the pro-apoptotic effector Ddit3 inhibits its expression. Moreover, we show that the Phlda3-mediated protection 
against stress involves the modulation of proinflammatory, adaptive UPR and antioxidant gene expression. Our 
results therefore suggest that Phlda3 is a novel adaptive gene induced under conditions of stress that promotes 
beta cell survival.
Material and Methods
Reagents. Cytokines IL1β, IFNγ and TNFα were obtained from R&D Systems (Minneapolis, MN, USA). 
Ribose, thapsigargin and 4-hydroxytamoxifen were from Sigma (St. Louis, MI, USA). Control Non-Targeting 
and ON-TARGETplus SMARTpool siRNAs and transfection reagent DharmaFECT3 were from Thermo Fisher 
Scientific (Lafayette, CO, USA).
Human islets. Human islets were obtained from 8 non-diabetic and 5 diabetic subjects at the Tom Mandel 
Islet Transplant Program in Melbourne21. Human islets were purified from heart-beating, brain-dead donors, 
with written informed consent from next of kin. All human studies were approved by the St Vincent’s Hospital 
Human Research Ethics Committee (approval number HREC011/04) and all methods were carried out in accord-
ance with guidelines and regulations. Characteristics of organ donors and islet preparations are indicated in 
Supplementary Table 1. To evaluate the impact of oxidative stress on Phlda3 protein expression ex vivo, human 
islets were obtained from 3 non-diabetic subjects through the JDRF award 31-2008-416 (ECIT Islet for Basic 
Research program) with written informed consent from next of kin and approved for use under the ethics ref-
erence B403/2017/05JUL/355 (Comité d'éthique hospitalo-facultaire Saint-Luc, UCLouvain). Characteristics 
of these donors and islet preparations are listed in Supplementary Table 2. All experiments were performed in 
accordance with relevant guidelines and regulations.
Mice. 14–16 weeks old C57BL/KsJ db/db mice and age-matched lean control mice (C57BL/KsJ), and 11–13 
weeks old female nonobese diabetic (NOD) mice and age-matched control Balb/c mice were obtained from the 
Garvan Institute breeding colonies (Australian BioResources, Moss Vale, NSW, Australia). Xbp1flox/flox mice were 
kindly provided by L.H. Glimcher and A.H. Lee (Weill Cornell Medical College, New York, NY, USA). They 
were crossed with Pdx1-CreER mice to generate Xbp1+/+-Pdx1-CreER (controls) and Xbp1flox/flox-Pdx1-CreER mice. 
For Xbp1 deletion, control and Xbp1flox/flox-Pdx1-CreER islets were treated with 100 nmol/l 4-hydroxytamoxifen 
as previously described14. For ex vivo islet experiments, 8–10 week-old wild-type C57BL/6 J mice were used. 
All experiments were approved by the Garvan Institute/St. Vincent’s Hospital Animal Experimentation Ethics 
Committee and by the Institutional Committee on Animal Experimentation of the Health Sciences Sector at 
UCLouvain (Project 2017/UCL/MD/014). All experiments were performed in accordance with relevant guide-
lines and regulations.
Islet isolation and culture. Islets were isolated by liberase digestion, separated by a density gradient and 
handpicked under a stereomicroscope. Islets were cultured in RPMI medium (Invitrogen, Carlsbad, CA, USA) 
containing 11.1 mmol/l glucose, 2 mmol/l glutamine, 10% heat-inactivated FBS, 50 units/ml penicillin and 50 µg/
ml streptomycin.
Cell culture. MIN6 beta cells (P26–43)22 were grown in Dulbecco’s modified Eagle’s medium (Invitrogen) 
containing 25 mmol/l glucose, 10 mmol/l HEPES, 10% FCS, 50 units/ml penicillin and 50 µg/ml streptomycin.
Islet and cell treatment. Isolated islets and cells were treated with 100 U/ml IL1β, 250 U/ml IFNγ and 100 
U/ml TNFα (15 min-24h). To assess the effects of lipotoxicity, islets and cells were treated with 0.92 g/100 ml BSA 
or 400 µmol/l palmitate coupled to 0.92 g/100 ml BSA (48 h). Thapsigargin (300 nmol/l, 1 µmol/l; 24 h) was used 
to induce ER stress. Ribose (50 mmol/l, 48 h) was used to induce oxidative stress. Cells were transfected with 100 
nmol/l control, Phlda3, Xbp1 or Ddit3 siRNA using DharmaFECT3 transfection reagent following manufactur-
er’s instruction. Human islets were cultured in RPMI medium containing 5.5 mmol/l glucose in the absence or 
presence of 50 µmol/l H2O2 for 24 h.
Apoptosis assay. Cell death was determined by quantification of cytoplasmic histone-associated DNA 
fragments using the Cell Death Detection ELISA (Roche Diagnostics, Castle Hill, NSW, Australia). Absorbance 
values were normalized to total DNA content measured by SYBR Green I (Roche Diagnostics, Castle Hill, NSW, 
Australia).
RNA analysis. Total RNA was extracted using RNAeasy kit (Qiagen, Victoria, Australia) and cDNA synthe-
sized using the QuantiTect reverse transcription kit (Qiagen, Victoria, Australia). Real-time RT-PCR was per-
formed using power SYBR Green PCR Master Mix and a 7900HT Real-Time PCR system (Applied Biosystems, 
Foster City, CA, USA). Primer sequences are listed in Supplementary Table 3. The value obtained for a specific 
gene product was normalized to the control gene cyclophilin A and expressed as a fold-change of the value in 
control condition. For human samples, RNA was extracted using Trizol and cDNA was synthesized using a ‘High 
Capacity cDNA Reverse Transcription Kit’ as previously described23. Taqman gene expression assays were used 
for Phlda3 (Hs00385313_ml) and the control gene Gapdh (Hs02758991_g1) (Applied Biosystems, Foster City, 
CA) using a TaqMan Fast Universal PCR Master Mix on a ViiA7 PCR machine.
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Protein analysis. Western blotting and band quantification were performed as previously described24,25. 
Phospho-v-akt murine thymoma viral oncogene homolog (AKT) (S473) and total AKT antibodies (9271 and 
9272) were from Cell Signaling (Danvers, MA USA) and actin antibody (A2066) from Sigma. Activation of 
Nuclear factor κB (NFκB) was assessed by quantification of subunit p65 phosphorylation (pS536) using the NFκB 
p65 (pS536) SimpleStep ELISA kit (ab176647, Abcam, Cambridge, UK). Absorbance values were normalized to 
total protein content measured with the Pierce BCA protein assay kit (Thermo Fisher Scientific, Lafayette, CO, 
USA).
Immunodetection of PHLDA3. After culture, cells on coverslips were washed with ice cold PBS and fixed 
in 4% paraformaldehyde for 15 min, permeabilized with PBS-Triton 0.05%, blocked with 5% BSA and incu-
bated overnight at 4 °C with goat polyclonal anti-PHLDA3 antibody (ab22822, Abcam, Cambridge, UK) diluted 
1:70 in 1% BSA. The next day, cells were washed and endogenous peroxidases inactivated with 3% H2O2 (vol/
vol) before incubation for 1 h at room temperature with HRP-conjugated donkey polyclonal anti-goat secondary 
antibody (705-035-003, Jackson ImmunoResearch) diluted 1:500 in 1% BSA. Human islets were washed and 
fixed in 4% paraformaldehyde for 4 h and embedded in paraffin. Antigen retrieval was performed on 5 µm islet 
sections using a microwave in the presence of citrate buffer (pH 5,7). Islet sections were then treated with 3% 
H2O2 (vol/vol), blocked with 5% BSA and incubated overnight at 4 °C with goat polyclonal anti-PHLDA3 anti-
body diluted 1:100 in 1% BSA. The next day, islet sections were incubated for 1 h at room temperature with 
HRP-conjugated secondary antibody diluted 1:500 in 1% BSA. For cells and islet sections, the signal was revealed 
by 3,3’-diaminobenzidine (K3468, DAKO, Carpintera, USA). Islet sections were counterstained with hematoxylin 
(S3301, DAKO). Insulin and glucagon immunostainings were performed on adjacent islet sections as previously 
reported24,25. Anti-insulin antibody (3014, Cell Signaling Technology, Danvers, MA, USA) was diluted 1:500 and 
anti-glucagon antibody (G2654, Sigma) was diluted 1:2000. Secondary Alexa fluor antibodies (Thermo Fisher 
Scientific) were diluted 1:1000.
Statistical analysis. Results are means ± SEM for the indicated number of experiments. Statistical signifi-
cance was assessed by unpaired two-tailed student t-test, one-way ANOVA and a post-test of Newman-Keuls or 
two-way ANOVA and a post-test of Bonferroni.
Results
Phlda3 mRNA levels are upregulated in the islets of diabetic mice and humans. We first assessed 
whether the Phlda3 expression is altered in diabetes. The mRNA levels of Phlda3 were markedly upregulated in 
the islets of db/db mice, a model of type 2 diabetes, in comparison to age-matched lean control C57BL/KsJ mice 
(Fig. 1a). In NOD mice, a model of type 1 diabetes, we found a significant upregulation of Phlda3 mRNA levels in 
comparison to control Balb/c mice (Fig. 1b). In humans, the mRNA levels of Phlda3 were markedly upregulated 
in the islets of type 2 diabetes donors in comparison to control subjects (Fig. 1c). These findings show for the first 
time that the expression of Phlda3 is upregulated in islets from diabetic rodents and humans. The findings raise 
two important questions: (1) what is (are) the mechanism(s) of Phlda3 induction in beta cells? and (2) what is the 
role(s) of Phlda3 in beta cell pathophysiology?
Phlda3 expression is induced by cytokine and palmitate treatment. To explore the mechanism(s) 
underlying Phlda3 induction in type 1 and type 2 diabetes, we exposed MIN6 cells and isolated mouse islets to 
factors that characterize the diabetic milieu, including proinflammatory cytokines and saturated free fatty acids3,6. 
We found that exposure of MIN6 cells to the cytokines IL1β, IFNγ and TNFα or the saturated fatty acid palmitate 
markedly upregulated the mRNA levels of Phlda3 (Fig. 2a,f) with parallel induction of ER stress (Ddit3, Trb3) and 
antioxidant (Hmox1) genes (Fig. 2b,c,g,h). In agreement, PHLDA3 protein immunostaining was also increased 
by cytokine (Fig. 2e) and palmitate (Fig. 2j) treatments. These treatments have previously been demonstrated to 
Figure 1. Phlda3 mRNA levels are upregulated in the islets of diabetic animal models and human subjects. 
Changes in the mRNA levels of Phlda3 in the islets of (a) control (C, white bar) and db/db mice (black bar), (b) 
control (C, white bar) and NOD mice (black bar) and (c) human non-diabetic (N, white bar) and type 2 diabetic 
(T2D, black bar) subjects. n = 6 animals per group for (a), n = 5–6 animals per group for (b) and n = 5–8 human 
subjects per group for (c). *p < 0.05, **p < 0.01, ***p < 0.001 vs control animals or non-diabetic subjects.
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be associated with increased beta cell death14. The upregulation of Phlda3 mRNA levels by cytokine and palmitate 
treatments was confirmed in primary mouse islets (Fig. 2d,i). These results suggest that Phlda3 is induced by 
common features of the diabetic environment in beta cells.
Phlda3 expression is induced by ER stress. ER stress is a key mechanism through which proinflamma-
tory cytokines and palmitate have been shown to affect rodent and human beta cells11,13,14,26,27. We therefore tested 
whether exposure of beta cells to the pharmacological ER stress inducer thapsigargin affected Phlda3 expression. 
Figure 2. Phlda3 mRNA and protein levels are upregulated by cytokine and palmitate treatment in parallel with 
the induction of ER stress and antioxidant genes. MIN6 cells (n = 4–9 experiments) or primary mouse islets 
(n = 5–10 experiments) were cultured in the absence (white bars) or presence (black bars) of cytokines (24 h) or 
palmitate (48 h). Changes in the mRNA levels of Phlda3, Ddit3, Trb3 and Hmox1 and PHLDA3 immunostaning 
in cytokine- (a–c,e) or palmitate-treated (f–h,j) MIN6 cells. Changes in the mRNA levels of Phlda3 in cytokine- 
(d) or palmitate-high glucose-treated (i) islets. **p < 0.01, ***p < 0.001 vs control. Scale bars, 50 µm.
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Interestingly, Phlda3 mRNA levels were markedly upregulated by thapsigargin treatment (Fig. 3a) in parallel 
with increased mRNA levels of adaptive (Hspa5, Hsp90b1 and Fkbp11) and proapoptotic (Ddit3 and Trb3) UPR 
genes (Fig. 3b–f). This finding was also confirmed at the protein level. Indeed, PHLDA3 protein immunostaining 
was markedly increased by thapsigargin treatment (Fig. 3g). These results demonstrate that Phlda3 is a novel ER 
stress-responsive gene in beta cells.
Phlda3 expression is induced by oxidative stress. Besides ER stress, cytokines and palmitate affect 
beta cells via the induction of oxidative stress. To determine the effects of oxidative stress on Phlda3 in beta 
cells, we exposed MIN6 cells to ribose. Ribose is a sugar that produces ROS more potently than glucose and is 
an established model of beta cell glucotoxicity and oxidative stress28,29. Ribose treatment strongly upregulated 
Phlda3 mRNA levels (Fig. 4a) with parallel upregulation of antioxidant genes (Hmox1, Gpx1 and Srxn1) (Fig. 4b). 
We also confirmed upregulation of Phlda3 mRNA levels by ribose treatment in primary mouse islets (Fig. 4c). 
In agreement, ribose treatment strongly increased PHLDA3 protein immunostaining in MIN6 cells (Fig. 4d). 
We next verified whether prolonged exposure to elevated glucose levels, thereby mimicking the diabetic milieu, 
may have an impact on Phlda3 expression. Interestingly, culture of mouse islets for 3 weeks in the presence of 
30 mmol/l glucose instead of 10 mmol/l markedly upregulated Phlda3 mRNA levels (Fig. 4e) in parallel with the 
upregulation of the antioxidant gene Srxn1 (Fig. 4f). Confirming these findings in humans, we found that expo-
sure of human islets to H2O2 strongly upregulated PHLDA3 immunostaining (Fig. 4g and Supplementary Fig. 1). 
Interestingly, insulin and glucagon immunostaining on adjacent islet sections revealed that PHLDA3 protein 
expression was induced throughout the islets in beta cells as well as in islet non-beta cells including alpha cells 
(Fig. 4g).
Figure 3. Phlda3 mRNA and protein levels are upregulated by thapsigargin treatment in parallel with the 
induction of ER stress genes. MIN6 cells were cultured for 24 h in the absence (white bars) or presence of 
300 nmol/l (grey bars) or 1000 nmol/l (black bars) thapsigargin (Tg). Changes in the mRNA levels of Phlda3, 
Hmox1, Trb3, Hspa5, Hsp90b1 and Fkbp11 (a–f) and PHLDA3 immunostaining (g). *p < 0.05, ***p < 0.001 vs 
control. ###p < 0.001 vs thapsigargin 300 nM. Scale bar, 50 µm.
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Altogether, these results demonstrate that, in addition to ER stress, Phlda3 is an oxidative stress responsive 
gene in beta cells.
Phlda3 is induced downstream of XBP1. ER stress triggers several signaling cascades in beta cells to 
restore homeostasis or otherwise induce apoptosis. X-box Binding Protein 1 (XBP1) is a key ER stress-inducible 
transcription factor that modulates the expression of several adaptive UPR genes including chaperones, foldases 
and components of the ER-associated degradation machinery14. It has previously been reported that Phlda3 
expression is regulated by XBP1 in hepatocytes20. To determine whether Phlda3 is regulated by XBP1 in beta cells, 
we used siRNA-mediated inhibition of Xbp1 expression in MIN6 cells14. In cytokine-treated MIN6 cells, Xbp1 
Figure 4. Phlda3 mRNA and protein levels are upregulated by oxidative stress-inducing agents in parallel with 
the induction of antioxidant genes. MIN6 cells or primary mouse islets were cultured in the absence (white 
bars) or presence of 50 mmol/l ribose for 48 h or high glucose (30 mmol/l) for 3 weeks (black bars). Human islets 
were cultured in the absence or presence of 50 µmol/l H2O2. Changes in the mRNA levels of Phlda3, Hmox1, 
Gpx1 and Srxn1 in ribose-treated MIN6 cells (a,b). Changes in the mRNA levels of Phlda3 in ribose-treated 
islets (c). Changes in PHLDA3 immunostaining in ribose-treated MIN6 cells (d). Changes in the mRNA levels 
of Phlda3 and Srxn1 in high glucose-treated islets (e,f). Changes in PHLDA3 immunostaining in H2O2-treated 
human islets and immunostaining for insulin and glucagon on adjacent islet sections (g). n = 3–5 experiments. 
**p < 0.01, ***p < 0.001 vs control. Scale bars, 50 µm.
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inhibition partially prevented Phlda3 mRNA induction (Fig. 5a). We also used islets from Xbp1flox/flox-Pdx1-CreER 
mice14. Phlda3 induction by cytokines was partially prevented in islets with beta cell specific XBP1 deficiency in 
comparison to control islets (Fig. 5b). Moreover, in the MIN6 cell model of lipotoxicity, Xbp1 inhibition using 
siRNA almost completely abolished the palmitate-mediated upregulation of Phlda3 mRNA (Fig. 5c). We have 
previously demonstrated that inhibition of Xbp1 is associated with increased cytokine and palmitate-induced cell 
death14. Taken together, the studies demonstrate a novel association between Xbp1-Phlda3 and protection against 
cytokine toxicity and lipotoxicity in beta cells. Conversely, siRNA-mediated inhibition of the proapoptotic UPR 
gene Ddit3 significantly upregulated the mRNA levels of Phlda3 under basal conditions and they tended to be 
increased after palmitate treatment (Fig. 5c).
Figure 5. Phlda3 induction under ER stress is downstream of XBP1. 4-Hydroxytamoxifen-treated control (C) 
and Xbp1flox/flox-Pdx1-CreER (Xbp1f/f) mouse islets (n = 7 experiments) and MIN6 cells transfected with either 
control siRNA (si-C), siRNA against Xbp1 (siXbp1) or siRNA against Ddit3 (siDdit3) (n = 9–12 experiments) 
were cultured in the absence (white bars) or presence (black bars) of cytokines (24 h) or palmitate (48 h). 
Changes in the mRNA levels of Phlda3 in cytokine-treated MIN6 cells (a) and primary islets (b). Changes in 
the mRNA levels of Phlda3 in palmitate-treated MIN6 cells (c). **p < 0.01, ***p < 0.001, ****p < 0.0001 vs 
untreated. #p < 0.05, ##p < 0.01 vs control siRNA or control islets.
Figure 6. Phlda3 knockdown potentiated cytokine- and ribose-induced apoptosis. MIN6 cells transfected 
with either control siRNA (si-C) or siRNA against Phlda3 (si-Ph3) were cultured in the absence (white bars) 
or presence (black bars) of cytokines (24 h, a,b) or ribose (48 h, c,d). Changes in (a,c) mRNA levels and (b,d) 
apoptosis. n = 3–4 experiments. *p < 0.05, **p < 0.01, ***p < 0.001 vs untreated. #p < 0.05, ###p < 0.001 vs 
control siRNA.
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Altogether, these results demonstrate that Phlda3 induction in beta cells is differentially regulated by adaptive 
(Xbp1) and proapoptotic UPR (Ddit3) effectors under conditions of cytokine and lipotoxic stress.
Phlda3 induction protects against cell death during stress. We next explored the role of Phlda3 in 
stressed beta cells. To this end, we evaluated cell death under stress conditions after siRNA-mediated inhibition 
of Phlda3 in MIN6 cells. Interestingly, we found that Phlda3 knockdown (Fig. 6a) potentiated cytokine-induced 
apoptosis (Fig. 6b). Similarly, under oxidative stress conditions induced by ribose treatment, Phlda3 knockdown 
(Fig. 6c) potentiated apoptosis (Fig. 6d). These results strongly suggest that Phlda3 induction in beta cells under 
stress is adaptive and may play an important role to promote survival.
Phlda3 regulates several stress response pathways in beta cells. The NFκB pathway. iNos 
is an important effector implicated in cytokine-mediated beta cell death26,30–32. Interestingly, we found that 
Phlda3 knockdown further increased iNos mRNA levels in control and cytokine-treated MIN6 cells (Fig. 7a). 
Since iNos is a downstream target of NFκB transcription factor33–35, we assessed the expression of Il1β and 
IκBα, two other known NFκB target genes. Remarkably, the mRNA levels of both genes were further upreg-
ulated in cytokine-treated MIN6 cells after Phlda3 knockdown (Fig. 7b,c). In agreement with these findings, 
cytokine-induced phosphorylation of NFκB subunit p65 on serine 536 (activation) was further increased after 
Phlda3 knockdown (Fig. 7d). Taken together, these results strongly suggest that NFκB activation is potentiated 
upon Phlda3 inhibition thereby leading to further upregulation of iNos, Il1β and IκBα. Therefore, the protective 
effect of Phlda3 induction under cytokines may stem, at least in part, from the repression of this pathway.
Evidence has suggested a role of the AKT pathway in NFκB activation in cancer cells36–38. Moreover, Phlda3 
has been proposed as a repressor of AKT39. Therefore, we assessed whether Phlda3 inhibition affected AKT phos-
phorylation (activation) after cytokine treatment. Under basal conditions, differences in the phosphorylated 
AKT/AKT ratio were not detected in cells transfected with control or Phlda3 siRNA (Fig. 7e,f). After cytokine 
treatment, AKT phosphorylation was rapidly and strongly reduced to a similar extent in cells transfected with 
control or Phlda3 siRNA (Fig. 7e,f). These results argue against a potential contribution of AKT to the enhanced 
activation of the NFκB pathway observed after Phlda3 inhibition.
The antioxidant response. Since cytokine treatment induces oxidative stress in beta cells, we assessed whether 
the inhibition of Phlda3 affected the antioxidant response. Interestingly, we found that cytokine-mediated upreg-
ulation of Gpx1 mRNA levels was prevented after Phlda3 inhibition (Fig. 8a). In addition, Srxn1 expression was 
reduced in cytokine-treated cells after Phlda3 inhibition (Fig. 8b). On the other hand, the mRNA levels of Hmox1 
were not affected (Fig. 8c). These results suggest that Phlda3 is required for maintaining an adequate expression 
of specific antioxidant genes under stress conditions.
Figure 7. Phlda3 inhibition potentiated cytokine-induced activation of the NFκB pathway independently 
of AKT. MIN6 cells transfected with either control siRNA (si-C) or siRNA against Phlda3 (si-Ph3) were 
cultured in the absence (white bars) or presence (grey and black bars) of cytokines (15min-24h). Changes in 
the mRNA levels of iNos, Il1β and Ikbα (a–c). Changes in the phosphorylation of NFκB subunit p65 on serine 
536 (d). Changes in phospho- and total AKT protein levels (e,f). n = 3–6 experiments. *p < 0.05, **p < 0.01, 
***p < 0.001 vs untreated. #p < 0.05, ##p < 0.01, ###p < 0.001 vs control siRNA.
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The adaptive UPR. We next assessed the influence of Phlda3 inhibition on the ability of cytokines to downreg-
ulate the adaptive UPR. We found that the mRNA levels of adaptive UPR genes were significantly lower (Xbp1, 
Hspa5, Fkbp11) or tended to be lower (Pdia4) following cytokine treatment in cells transfected with Phlda3 siRNA 
compared to control siRNA (Fig. 8d–g). On the other hand, the cytokine-mediated upregulation of the proapop-
totic UPR gene Ddit3 was not different between control siRNA- and Phlda3 siRNA-treated cells (Fig. 8h). These 
results suggest that Phlda3 partially protects against the loss of adaptive UPR gene expression during inflamma-
tory stress.
Finally, we tested whether the inhibition of Phlda3 influences cytokine-mediated beta cell dedifferentiation40. 
We found that the cytokine-mediated downregulation of beta cell genes Mafa and Slc2a2 (also known as Glut2) 
was not affected by Phlda3 knockdown (Fig. 8i,j). Furthermore, the cytokine-induced upregulation of genes asso-
ciated with beta cell dedifferentiation, Id1 and Cdkn1a (also known as p21) were not affected by Phlda3 inhibition 
(Fig. 8k,l).
All together, these results demonstrate that Phlda3 plays an important adaptive role under stress conditions via 
the modulation of several stress responses including the NFκB pathway, the antioxidant response and the UPR. 
Our studies suggest that Phlda3 expression may be beneficial for preserving beta cell mass during the pathogen-
esis of diabetes.
Discussion
The elevated levels of fatty acids, glucose and proinflammatory cytokines of the (pre)diabetic environment play a 
major role in triggering beta cell stress and demise3–5,41. The complex interaction of stress-activated adaptive and 
proapoptotic responses determines the fate of beta cells. However, knowledge of the stress response pathways in 
beta cells is incomplete, which has hampered the development of strategies to preserve beta cell mass in diabetic 
subjects. In the present study, we have identified Phlda3 as a novel stress-responsive gene in beta cells. We report 
for the first time that: (1) Phlda3 is upregulated in islets of diabetic rodents and humans; (2) Phlda3 expres-
sion is induced in response to the major stress conditions associated with beta cell failure in diabetes, namely 
Figure 8. Phlda3 inhibition negatively impacts antioxidant and adaptive UPR gene expression without affecting 
cytokine-induced alterations of beta cell differentiation. MIN6 cells transfected with either control siRNA 
(si-C) or siRNA against Phlda3 (si-Ph3) were cultured in the absence (white bars) or presence (black bars) of 
cytokines (24 h). Changes in the mRNA levels of (a–c) antioxidant genes, (d–g) adaptive UPR gene, (h) Ddit3, 
(i,j) beta cell enriched genes and (k,l) genes involved in beta cell dedifferentiation. n = 4 experiments. *p < 0.05, 
***p < 0.001 vs untreated. #p < 0.05, ##p < 0.01, ###p < 0.001 vs control siRNA.
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inflammatory, ER and oxidative stress; and (3) Phlda3 plays an important adaptive role to protect against beta cell 
death during stress (Fig. 9).
Beta cells are highly vulnerable to ER stress because of their heavy engagement in proinsulin biosynthesis. 
Therefore, an intact and fine-tuned adaptive UPR is vital for beta cell viability. Indeed, previous evidence linked 
the failure of this response with beta cell decompensation and progression to diabetes42–44. Interestingly, our 
data suggest that Phlda3 plays a complex role both downstream and upstream of the XBP1 arm of the adaptive 
UPR (Fig. 9). Thus, we found that Xbp1 was required for stress-induced upregulation of Phlda3 in MIN6 cells 
and primary mouse islets. The Xbp1-dependent upregulation of Phlda3 is in agreement with previous findings 
in hepatocytes20. However, in the latter study, Phlda3 contributed to ER stress-mediated hepatocyte death20, in 
opposition to the protective role of Phlda3, and Xbp114, in stressed beta cells. These findings are suggestive of 
distinct tissue-specific roles of Xbp1-Phlda3 signalling during stress. Interestingly, inhibition of the proapoptotic 
ER stress gene Ddit3 was associated with marked upregulation of Phlda3 mRNA levels. This further supports the 
notion that Phlda3 is protective in beta cells since Ddit3 inhibition is associated with improved beta cell survival 
in vitro14,25 and in vivo12.
Moreover, our findings identify a previously unrecognized role of Phlda3 as an upstream regulator of adaptive 
UPR gene expression. Thus, Phlda3 inhibition reduced adaptive UPR gene mRNA levels after cytokine treatment 
(Fig. 8d–g). Interestingly, under these conditions Phlda3 inhibition potentiated the upregulation of iNos (Figs 7a 
and 9). Notably, nitric oxide is a known repressor of the adaptive UPR32. Thus, changes in iNos activation may 
provide a mechanism whereby Phlda3 regulates the adaptive UPR following cytokine stimulation.
In addition to iNos, Phlda3 inhibition resulted in the upregulation of other NFκB target genes (Il1β and Ikbα) 
in parallel with increased NFκB phosphorylation. This raises the possibility that Phlda3 acts as a brake on NFκB 
activation. Since the NFκB pathway is considered proapoptotic in beta cells45, the findings further support a 
protective role for Phlda3. How this repression may operate is unclear. We investigated AKT as a candidate 
because previous studies have linked it both with NFκB activation36–38 and repression by Phlda339. However, in 
our model, the phosphorylation of AKT (activation) was unaffected by Phlda3 inhibition under both basal con-
ditions and following cytokine treatment (Fig. 7e,f). This suggests that the regulation of NFκB by Phlda3 occurs 
independently of AKT. Alternatively, cytokine treatment triggers oxidative stress with subsequent upregulation 
of antioxidant genes. Oxidative stress can also upregulate the expression of inflammatory genes in beta cells46. 
Therefore, dysregulation of the antioxidant response such as occurs with Phlda3 inhibition (reduced Gpx1 and 
Srxn1 mRNA levels, Fig. 8a,b) may lead to more severe oxidative stress. Accordingly, one could postulate that 
enhanced expression of NFκB target genes may result from increased oxidative stress under these conditions.
Our findings contrast with a recent report showing that islets from mice with Phlda3 deletion are more resist-
ant to hypoxic stress in the context of islet transplantation47. In our model, Phlda3 knockdown had no significant 
effect on hypoxia-induced apoptosis (Supplementary Fig. 2). The reasons for these discrepant results are not 
clear. The studies of Sakata et al. adopted mice with constitutive whole body knockout of Phlda3. This raises the 
possibility of developmental effects in the knockout islets that are independent of Phlda3 expression in adult beta 
cells. Indeed, the Phlda3 knockout mice display a complex phenotype with the potential for metabolic changes 
Figure 9. The proposed model. The elevated levels of proinflammatory cytokines, fatty acids and glucose play 
a key role in triggering beta cell stress and demise. Phlda3 is a novel adaptive beta cell stress response gene 
induced downstream of XBP1 that promotes beta cell survival via the repression of the NFκB pathway and the 
maintenance of adequate antioxidant and adaptive UPR gene expression. FFA; free fatty acids, NO; nitric oxide, 
ROS; reactive oxygen species, T1D; type 1 diabetes, T2D; type 2 diabetes.
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in other tissues secondarily influencing islets. Phlda3 knockout mice develop islet hyperplasia only later in life 
with an altered distribution of small and large islets. Perhaps Phlda3 affects the stress response during beta cell 
ageing48,49, which may influence islet transplantation outcomes in the longer term47. Together with the knowledge 
that Phlda1 regulates insulin sensitivity and energy expenditure18, it is clear that experiments that employ induc-
ible beta cell specific modulation of Phlda3 are needed. Moreover, hypoxic stress may involve unique regulatory 
networks compared with other stressors in beta cells, as exemplified by the strong suppression of XBP1 protein 
levels and downstream target genes25.
Interestingly, in mouse islets, Phlda3 mRNA levels were markedly upregulated in the type 2 diabetes model 
(Fig. 1a), but displayed comparatively modest induction in the type 1 diabetes model (Fig. 1b). This may be 
related to differences in the nature or duration of the diabetes stress conditions between these models. Finally, 
the observation that oxidative stress upregulated PHLDA3 expression in both beta and non-beta cells in human 
islets suggests that PHLDA3 may have a potential role in islet non-beta cells, including alpha cells, which are also 
crucial for glucose homeostasis. Therefore, upregulated mRNA levels of Phlda3 in human T2D islets may involve 
an effect in both beta and non-beta cells.
In conclusion, we have unveiled a novel role of Phlda3 in beta cell pathophysiology. Our studies show for 
the first time that: (1) Phlda3 is upregulated in the islets of diabetic mice and humans; (2) Phlda3 is induced by 
inflammatory, ER and oxidative stress; (3) Phlda3 is regulated positively by the adaptive UPR mediator, Xbp1 and 
negatively by the proapoptotic UPR mediator, Ddit3; and (4) Phlda3 contributes to the adaptive response to stress 
through modulation of the NFκB pathway, specific antioxidant genes and the adaptive UPR. These observations 
reveal a novel molecular mechanism regulating beta cell survival during stress and suggest the targeting of the 
Xbp1-Phlda3 axis as a potential therapeutic strategy in diabetes.
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